France registers five new cases of thrombosis among those vaccinated with AstraZeneca, no deaths reported
Since the start of the vaccination campaign, 3.2 million doses of AstraZeneca have been injected in France.
France registered five new cases of atypical thrombosis associated with the AstraZeneca vaccine between April 9 and 15, although none caused death, according to health authorities.
The people who suffered from this pathology had an average age of 63 years, indicated the French Medicines Agency (ANSM). Since March 19, the AstraZeneca vaccine against covid-19 has only been applied in France from the age of 55.
Since the start of the vaccination campaign, 3.2 million doses of AstraZeneca have been injected. In total, there were 27 cases of thrombosis, of which 8 led to death.
"The typology of declared cases is identical to that of the last balance," the ANSM reported, specifying that among the 27 cases, 13 were women and 14 men.
Due to the rare cases of thrombosis detected in Europe especially among the younger population after vaccination with the AstraZeneca immunizer, many countries decided to stop supplying it below a certain age.
In France, people under 55 who have already received a first dose will receive a second with the Pfizer and Moderna vaccines.
The European Medicines Agency (EMA) said on Friday that a review it conducted of the AstraZeneca vaccine shows that its benefits increase with age and that these outweigh the risks.
The people who suffered from this pathology had an average age of 63 years, indicated the French Medicines Agency (ANSM). Since March 19, the AstraZeneca vaccine against covid-19 has only been applied in France from the age of 55.
Since the start of the vaccination campaign, 3.2 million doses of AstraZeneca have been injected. In total, there were 27 cases of thrombosis, of which 8 led to death.
"The typology of declared cases is identical to that of the last balance," the ANSM reported, specifying that among the 27 cases, 13 were women and 14 men.
Due to the rare cases of thrombosis detected in Europe especially among the younger population after vaccination with the AstraZeneca immunizer, many countries decided to stop supplying it below a certain age.
In France, people under 55 who have already received a first dose will receive a second with the Pfizer and Moderna vaccines.
The European Medicines Agency (EMA) said on Friday that a review it conducted of the AstraZeneca vaccine shows that its benefits increase with age and that these outweigh the risks.
AI Disclaimer: An advanced artificial intelligence (AI) system generated the content of this page on its own. This innovative technology conducts extensive research from a variety of reliable sources, performs rigorous fact-checking and verification, cleans up and balances biased or manipulated content, and presents a minimal factual summary that is just enough yet essential for you to function as an informed and educated citizen. Please keep in mind, however, that this system is an evolving technology, and as a result, the article may contain accidental inaccuracies or errors. We urge you to help us improve our site by reporting any inaccuracies you find using the "Contact Us" link at the bottom of this page. Your helpful feedback helps us improve our system and deliver more precise content. When you find an article of interest here, please look for the full and extensive coverage of this topic in traditional news sources, as they are written by professional journalists that we try to support, not replace. We appreciate your understanding and assistance.
